What is the main business of Vaxican?

The main business activity of Vaxican focuses on research and experimental development in natural sciences and engineering.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on September 12, 2019.

Where is the headquarters located?

The headquarters is located at: ul. Kampinoska 25, 80-180 Gdańsk.

What is the share capital?

The share capital of the company is PLN 109,850 (approx. $29,673).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.

What revenue was generated?

The company reported a revenue of USD 390,934 in 2025, which is an increase of 3586.0% compared to 2024.

No, in 2025 the company was not profitable, reporting a net loss of USD 369,516. For comparison, in 2024 the loss was USD 220,687, meaning the company increased its loss by 67.1%.

What is the largest operating cost?

The largest operating cost category falls under employee remuneration. This category amounted to USD 296,323 in 2025, representing 40% of all operating expenses.

Vaxicansp. z o.o.

Research and experimental development in natural sciences and engineering

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2019-09-12

Share capital

109 850,00 PLN

Activity description

Vaxican is a startup developing cancer immunotherapies based on virus-like particles to stimulate humoral and cellular immune responses. Through Vaxican Genomics, it provides whole-genome sequencing for microorganisms and targeted DNA and RNA sequencing for humans and animals using Oxford Nanopore technology.

Registered address

ul. Kampinoska 25, 80-180 Gdańsk, Poland

Website

vaxican.com

Electronic delivery address

AE:PL-96630-67794-FSSUB-21

Financials

Revenue history (in k)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 390.93kMedianUSD 133.91kAverageUSD 4.65m

Net profit

This companyUSD -369.52kMedianUSD -54.78AverageUSD 310.10k

Operating costs

This companyUSD 749.38kMedianUSD 175.72kAverageUSD 4.46m

Assets

This companyUSD 1.59mMedianUSD 254.44kAverageUSD 8.12m

Industry

Bank accounts

Registered as a VAT taxpayer on 2019-10-19. Active

ING Bank Śląski
89 1050 1764 1000 0090 8188 1279
ING Bank Śląski
90 1050 1764 1000 0090 8188 1261
ING Bank Śląski
17 1050 1764 1000 0090 8604 1838

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

Public aid

5 public aid cases recorded, with a total value of $2,378,620.

Grant date	Purpose	Gross amount	Granting body
Nov 20, 2025	Aid for SMEs for innovation support	––	Prezes Banku Gospodarstwa Krajowego
May 2, 2025	De minimis aid (in accordance with Commission Regulation 2023/2831)	––	Prezes Banku Gospodarstwa Krajowego
Apr 24, 2025	Aid for research and development projects: industrial research	––	Prezes Agencji Badań Medycznych

European Funds

Start	Project	EU co-financing	Programme
2026-03-01	Innowacyjne metody diagnostyczne i terapeutyczne wobec zwiększonego zagrożenia arbowirusami spowodowanego zmianami klimatycznymi	$1.2M$1,209,243	Fundusze Europejskie dla Pomorza 2021-2027

Tenders

1 tender recorded as contractor, with a total value of $81,578.

Publication date	Subject	Amount	Contracting authority
Jun 30, 2026	Kompleksowe usługi sekwencjonowania - 2 zadania	$81,578$81,578	Narodowy Instytut Geriatrii,Reumatologii I Rehabilitacji Im. Prof. Dr Hab. Med. Eleonory Reicher

Authorized Representatives

Łukasz Bartosz Rąbalski – President of the Management Board

Krzysztof Łepek – Vice President of the Management Board

Mateusz Sagan – Vice President of the Management Board

Manner of representation

In the case of a one-person management board, a member of the management board will be authorized to submit declarations on behalf of the company independently; in the case of a multi-member management board, two members of the management board acting jointly or one member of the management board together with a commercial proxy acting jointly will be authorized to submit declarations on behalf of the company.

Supervisory board

Maciej Grzybek – Supervisory Board Member

Martyna Krejmer Rąbalska – Supervisory Board Member

Krzysztof Laskowski – Supervisory Board Member

Maciej Tadeusz Wieloch – Supervisory Board Member

Marcin Śledź – Supervisory Board Member

Ownership

Owner	Shares	Share value	Stake
Iif.Vc S.K.A.	568	$7,671.53	25.8534%
Łukasz Bartosz Rąbalski (44)	552	$7,455.43	25.1252%
Rubicon Partners Ventures sp. z o.o.	353	$4,767.69	16.0674%
Others	724	$9,778.50	32.954%

Beneficial owners

Person	Rights

Competitors

Name	Revenue	Website
GenxoneS.A.	$665,361.35	genxone.eu
FamicordtxS.A.	$589,673.84	famicordtx.com
VET Cell Techsp. z o.o.	$483,439.81	vetcelltech.com
Vasa Therapeuticssp. z o.o.	$363,111.30	vasatherapeutics.com
Medicofarma BiotechS.A.	$314,882.33	medicofarmabiotech.pl
Explorna Therapeuticssp. z o.o.	$304,662.00	explorna.com
MultiqureS.A.	$284,781.52	purebiologics.com
Rivbiosp. z o.o.	$266,377.70	rivbio.com
Vitrotest Europesp. z o.o.	$233,350.77	vitrotest.pl
Nexbiosp. z o.o.	$186,582.40	nexbio.pl

Change history

Date	Event
2026-08-10	Share capital change (60,000.00 PLN → 109,850.00 PLN)
2026-08-10	PKD change (Removed: 46.46.Z, 74.14.Z, 82.30.Z; Added: 75.00.Z, 86.91.B, 86.99.D)
2026-04-09	Address change (Ul. Kładki 24, 80-822, Gdańsk → Ul. Kampinoska 25, 80-180, Gdańsk)
2025-08-05	Share capital change (5,000.00 PLN → 60,000.00 PLN)
2025-08-05	PKD change (Removed: 71.20.B, 72.11.Z, 72.19.Z, 74.10.Z; Added: 21.10.Z, 21.20.Z, 46.46.Z, 70.20.Z, 71.20.C, 72.10.Z, 74.14.Z, 74.99.Z, 77.40.B)

FAQ

Last updated: 2026-10-04